


Amendments to the Claims:

1. (Original/Currently Amended) A compound of formula (I),



wherein

m is 1, 2 or 3;

R<sup>1</sup> is methyl, chloro, bromo or fluoro;

R<sup>2</sup> is -Q<sup>1</sup>-Q<sup>2</sup>-Q<sup>3</sup>-Q<sup>4</sup> or (C<sub>1</sub>-C<sub>6</sub>)alkyl,

- said (C<sub>1</sub>-C<sub>6</sub>)alkyl is substituted with one to three OR<sup>4</sup>, COOR<sup>4</sup>, NR<sup>4</sup>R<sup>5</sup>, NRC(=O)R<sup>4</sup>, C(=O)NR<sup>4</sup>R<sup>5</sup> or SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>;
- R<sup>4</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl substituted with one to three F, CN, S(=O)R<sup>6</sup>, SO<sub>3</sub>H, SO<sub>2</sub>R<sup>6</sup>, SR<sup>7</sup>, C(=O)-NH-SO<sub>2</sub>-CH<sub>3</sub>, C(=O)R<sup>7</sup>, NR'C(=O)R<sup>7</sup>, NR'SO<sub>2</sub>R<sup>6</sup>, C(=O)NR<sup>7</sup>R<sup>8</sup>, O-C(=O)NR<sup>7</sup>R<sup>8</sup> or SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>;
- R<sup>5</sup> is H or (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three F, CN, S(=O)R<sup>6</sup>, SO<sub>3</sub>H, SO<sub>2</sub>R<sup>6</sup>, SR<sup>7</sup>, C(=O)-NH-SO<sub>2</sub>-CH<sub>3</sub>, C(=O)R<sup>7</sup>, NR'C(=O)R<sup>7</sup>, NR'SO<sub>2</sub>R<sup>6</sup>, C(=O)NR<sup>7</sup>R<sup>8</sup>, O-C(=O)NR<sup>7</sup>R<sup>8</sup> or SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>; or
- said (C<sub>1</sub>-C<sub>6</sub>)alkyl is
  - 1) substituted with one to three OC(=O)R<sup>4a</sup>, SR<sup>4a</sup>, S(=O)R<sup>3</sup>, C(=NR<sup>5</sup>)R<sup>4a</sup>, C(=NR<sup>5</sup>)-NR<sup>4a</sup>R<sup>5a</sup>, NR-C(=NR<sup>5</sup>)-NR<sup>4a</sup>R<sup>5a</sup>, NRCOOR<sup>4a</sup>, NR-C(=O)-NR<sup>4a</sup>R<sup>5a</sup>, NR-SO<sub>2</sub>-NR<sup>4a</sup>R<sup>5a</sup>, NR-C(=NR<sup>5</sup>)-R<sup>4a</sup> or NR-SO<sub>2</sub>-R<sup>3</sup>; and
  - 2) optionally substituted with one or two OR<sup>4a</sup>, COOR<sup>4a</sup>, C(=O)-R<sup>4a</sup>, NR<sup>4a</sup>R<sup>5a</sup>, NRC(=O)R<sup>4a</sup>, C(=O)NR<sup>4</sup>R<sup>5a</sup> or SO<sub>2</sub>NR<sup>4a</sup>R<sup>5a</sup>;
- R<sup>9</sup> is H, CN, OH, OCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>NH<sub>2</sub> or (C<sub>1</sub>-C<sub>6</sub>)alkyl; and
- R<sup>3</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three F, CN, S(=O)R<sup>6</sup>, SO<sub>3</sub>H, SO<sub>2</sub>R<sup>6</sup>, C(=O)-NH-SO<sub>2</sub>-CH<sub>3</sub>, OR<sup>7</sup>, SR<sup>7</sup>, COOR<sup>7</sup>, C(=O)R<sup>7</sup>, O-C(=O)NR<sup>7</sup>R<sup>8</sup>, NR<sup>7</sup>R<sup>8</sup>, NR'C(=O)R<sup>7</sup>, NR'SO<sub>2</sub>R<sup>6</sup>, C(=O)NR<sup>7</sup>R<sup>8</sup> or SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>;

- $R^{4a}$  and  $R^{5a}$  are the same or different and are H or  $(C_1-C_6)$ alkyl optionally substituted with one to three F, CN,  $S(=O)R^6$ ,  $SO_3H$ ,  $SO_2R^6$ ,  $C(=O)-NH-SO_2-CH_3$ ,  $OR^7$ ,  $SR^7$ ,  $COOR^7$ ,  $C(=O)R^7$ ,  $O-C(=O)NR^7R^8$ ,  $NR^7R^8$ ,  $NR^7C(=O)R^7$ ,  $NR^7SO_2R^6$ ,  $C(=O)NR^7R^8$  or  $SO_2NR^7R^8$ ;  
 $Q^1$  is a single bond or  $(C_1-C_6)$ alkylene;  
 $Q^2$  is a saturated 4- to 6-membered heterocyclyl comprising one or two O or N;  
 $Q^3$  is  $(C_1-C_6)$ alkylene;  
 $Q^4$  is a 4 to 8-membered, aromatic or non aromatic, heterocyclyl comprising 1 to 4 -O-, -S-, -S(=O)-, -SO<sub>2</sub>- or -N-, said heterocyclyl being optionally substituted with one to three -OR, -NRR', -CN or  $-(C_1-C_6)$ alkyl;  
R is H or  $(C_1-C_6)$ alkyl;  
 $R^6$  is  $(C_1-C_6)$ alkyl optionally substituted with one or two -OR';  
 $R^7$  and  $R^8$  are the same or different and are H or  $(C_1-C_6)$ alkyl optionally substituted with one or two -OR';  
 $R^9$  is H, -CN, -OH, -OCH<sub>3</sub>, -SO<sub>2</sub>CH<sub>3</sub>, -SO<sub>2</sub>NH<sub>2</sub> or  $-(C_1-C_6)$ alkyl;  
R' is H or  $(C_1-C_6)$ alkyl; and  
R'' is H or  $(C_1-C_6)$ alkyl;  
provided that
  - 1) the atom of  $Q^2$  bound to  $Q^1$  is a carbon atom; and
  - 2) the atom of  $Q^4$  bound to  $Q^3$  is a carbon atom;
or a racemic form, isomer, pharmaceutically acceptable salts, hydrates, solvates and polymorphs derivative thereof.

2. (Original) A compound of claim 1 wherein  $R^2$  is  $(C_1-C_6)$ alkyl substituted with -OR<sup>4</sup>, -COOR<sup>4</sup>, -NR<sup>4</sup>R<sup>5</sup>,  $NRC(=O)R^4$ ,  $-C(=O)NR^4R^5$  or -SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>; R<sup>4</sup> is  $(C_1-C_6)$ alkyl substituted with one to three -S(=O)R<sup>6</sup>, -SO<sub>2</sub>R<sup>6</sup>, -NR<sup>7</sup>C(=O)R<sup>7</sup>, -NR<sup>7</sup>SO<sub>2</sub>R<sup>6</sup>, -C(=O)NR<sup>7</sup>R<sup>8</sup>, -O-C(=O)NR<sup>7</sup>R<sup>8</sup> or SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>; R<sup>5</sup> is H or  $(C_1-C_6)$ alkyl optionally substituted with one to three -S(=O)R<sup>6</sup>, -SO<sub>2</sub>R<sup>6</sup>, -NR<sup>7</sup>C(=O)R<sup>7</sup>, -NR<sup>7</sup>SO<sub>2</sub>R<sup>6</sup>, -C(=O)NR<sup>7</sup>R<sup>8</sup>, -O-C(=O)NR<sup>7</sup>R<sup>8</sup> or SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>; R<sup>6</sup> is  $(C_1-C_6)$ alkyl; and R', R<sup>7</sup> and R<sup>8</sup> are the same or different and are H or  $(C_1-C_6)$ alkyl.

3. (Original) A compound of claim 1 wherein  $R^2$  is  $(C_1-C_4)$ alkyl substituted with  $-NR^4R^5$  or  $-C(=O)NR^4R^5$ ;  $R^4$  is  $(C_1-C_6)$ alkyl substituted with  $-S(=O)CH_3$ ,  $-NHC(=O)CH_3$  or  $-C(=O)NR^7R^8$ ;  $R^5$  is H or methyl; and  $R^7$  and  $R^8$  are the same or different and are H or methyl.
4. (Original) A compound of claim 1 wherein  $R^2$  is  $(C_1-C_6)$ alkyl substituted with one to three  $-OC(=O)R^{4a}$ ,  $-SR^{4a}$ ,  $-S(=O)R^3$ ,  $-NR^4COOR^{4a}$ ,  $-NR-C(=O)-NR^{4a}R^{5a}$ ,  $-NR-SO_2-NR^{4a}R^{5a}$  or  $-NR-SO_2-R^3$ ; and said  $(C_1-C_6)$ alkyl is optionally substituted with  $-OH$  or  $-OCH_3$ ;  $R$  is H or  $CH_3$ ;  $R^3$  is  $(C_1-C_6)$ alkyl optionally substituted with one to three  $-F$ ,  $-CN$ ,  $-S(=O)R^6$ ,  $-SO_3H$ ,  $-SO_2R^6$ ,  $-C(=O)-NH-SO_2-CH_3$ ,  $-OR^7$ ,  $-SR^7$ ,  $-COOR^7$ ,  $-C(=O)R^7$ ,  $-O-C(=O)NR^7R^8$ ,  $-NR^7R^8$ ,  $-NR^7C(=O)R^7$ ,  $-NR^7SO_2R^6$ ,  $-C(=O)NR^7R^8$  or  $-SO_2NR^7R^8$ ;  $R^{4a}$  and  $R^{5a}$  are the same or different and are H,  $(C_1-C_6)$ alkyl optionally substituted with one to three  $-F$ ,  $-CN$ ,  $-S(=O)R^6$ ,  $-SO_3H$ ,  $-SO_2R^6$ ,  $-C(=O)-NH-SO_2-CH_3$ ,  $-OR^7$ ,  $-SR^7$ ,  $-COOR^7$ ,  $-C(=O)R^7$ ,  $-O-C(=O)NR^7R^8$ ,  $-NR^7R^8$ ,  $-NR^7C(=O)R^7$ ,  $-NR^7SO_2R^6$ ,  $-C(=O)NR^7R^8$  or  $-SO_2NR^7R^8$ ;  $R^6$  is  $(C_1-C_6)$ alkyl; and  $R^7$ ,  $R^7$  and  $R^8$  are the same or different and are H or  $(C_1-C_6)$ alkyl.
5. (Original) A compound of claim 1 wherein  $R^2$  is  $(C_1-C_6)$ alkyl substituted with  $-S(=O)R^3$ ;  $R^3$  is  $(C_1-C_6)$ alkyl optionally substituted with one to three  $-S(=O)R^6$ ,  $-SO_2R^6$ ,  $-NR^7R^8$ ,  $-OR^7$ ,  $-NR^7C(=O)R^7$ ,  $-NR^7SO_2R^6$ ,  $-C(=O)NR^7R^8$ ; or  $-O-C(=O)NR^7R^8$ ;  $R^6$  is  $(C_1-C_6)$ alkyl; and  $R^7$ ,  $R^7$  and  $R^8$  are the same or different and are H or  $(C_1-C_6)$ alkyl.
6. (Original) A compound of claim 1 wherein  $R^2$  is  $(C_1-C_6)$ alkyl substituted with  $-S(=O)R^3$ ; and  $R^3$  is  $(C_1-C_6)$ alkyl, preferably methyl.
7. (Original) A compound of claim 1 wherein  $R^2$  is  $Q^1-Q^2-Q^3-Q^4$ ;  $Q^2$  is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom;  $Q^3$  is a linear  $(C_1-C_4)$ alkylene group;  $Q^4$  is a 5- or 6-membered aromatic heterocycle comprising one to four nitrogen atoms, said heterocycle being optionally substituted with methyl.

8. (Original) A compound of claim 1 wherein  $R^2$  is  $Q^1-Q^2-Q^3-Q^4$ ;  $Q^1$  is a single bond;  $Q^2$  is a saturated 4 to 6-membered heterocycle comprising a nitrogen atom;  $Q^3$  is  $-CH_2-$ ; and  $Q^4$  is a 5-membered, aromatic heterocycle comprising 2 nitrogen atoms, said heterocycle being optionally substituted with methyl.
9. (Original) A compound of claim 8 wherein  $R^1$  is -Cl or -F.
10. (Original) A compound of claim 8 wherein m is 2.
11. (Original~~Canceled~~ Currently Amended) A compound according to claim 8 and selected from  
5'-(2-((2-amino-2-oxoethyl)amino)ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;  
8'-chloro-5'-((methylsulfinyl)methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;  
5'-(2-([2-(acetylamino)ethyl]amino)ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;  
8'-fluoro-5'-[3-(methylsulfinyl)propoxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;  
8'-fluoro-5'-((methylsulfinyl)methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one; or  
8'-fluoro-5'-(2-([1-(1H-pyrazol-3-ylmethyl)azetidin-3-yl]oxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one.
12. (Original~~Canceled~~) ~~A method of treating a disease for which PDE7 inhibition therapy is indicated in a mammal comprising administering to said mammal in need thereof a compound of claim 1.~~
13. (Original~~Canceled~~ Currently Amended) A method of claim 12 wherein said treating a disease is selected from T-cell-related diseases, autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer, leukemia, acquired immune deficiency syndrome (AIDS),

~~allergy, inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, pancreatitis, dermatoses, psoriasis, atopic dermatitis, glomerulonephritis, conjunctivitis, autoimmune diabetes, graft rejection, epilepsy, muscular atrophy and systemic lupus erythematosus~~ in a mammal comprising administering to said mammal in need thereof, a compound of claim 1.

14. (Original) A method of claim 13 wherein said disease is asthma, allergy or atopic dermatitis.
15. (Original) A method of claim 13 wherein said disease is osteoporosis.
16. (Original) A method of claim 13 wherein said disease is cancer.
17. (Original) A pharmaceutical composition comprising a compound of claim 1 together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.